Innovation1 Biotech Inc. (IVBT)

Innovation1 Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is September - August.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020	Aug 31, 2019
Net Income	-5.99	-40.88	1.04	-2.58	-0.17
Depreciation & Amortization	0.05	2.55	0	0	0
Other Amortization	-	-	-	-0.3	0.02
Asset Writedown & Restructuring Costs	3.48	35.78	0.02	0.08	0
Loss (Gain) From Sale of Investments	-	-	-0.01	-0	-
Stock-Based Compensation	0.1	-	-	-	0.02
Other Operating Activities	0.46	-0.14	-1.34	1.69	-0.49
Change in Accounts Receivable	-	-0.06	-	-	0
Change in Inventory	-	-	0	0.17	-0.15
Change in Accounts Payable	-0.25	-0.04	0.13	0.42	-0.01
Change in Other Net Operating Assets	1.52	-0.33	0.12	0.11	0
Operating Cash Flow	-0.62	-3.13	-0.03	-0.41	-0.78
Capital Expenditures	-	-0.85	-	-	-0.01
Other Investing Activities	-	-	-	-0.3	-
Investing Cash Flow	-	-0.85	-	-0.3	-0.01
Short-Term Debt Issued	0.03	-	0.15	0.83	0.03
Long-Term Debt Issued	0.49	-	-	-	-
Total Debt Issued	0.51	-	0.15	0.83	0.03
Short-Term Debt Repaid	-	-	-	-0.04	-
Total Debt Repaid	-	-	-	-0.04	-
Net Debt Issued (Repaid)	0.51	-	0.15	0.79	0.03
Repurchase of Common Stock	-	-	-	-0.08	-
Financing Cash Flow	0.51	4	0.15	0.71	0.03
Net Cash Flow	-0.11	0.02	0.12	-0	-0.76
Free Cash Flow	-0.62	-3.98	-0.03	-0.41	-0.78
Free Cash Flow Margin	-	-	-987.18%	-34737.34%	-987.42%
Free Cash Flow Per Share	-0.03	-0.26	-0.16	-1.37	-1.79
Cash Interest Paid	-	0.04	-	-	-
Levered Free Cash Flow	-27.01	27.66	-1.94	-0.14	-1.03
Unlevered Free Cash Flow	-26.86	27.66	-1.81	1.51	-1.04
Change in Net Working Capital	26.22	-29.26	1.65	-1.94	0.64

Source: S&P Global Market Intelligence. Standard template. Financial Sources.